Intravitreal ranibizumab for choroidal neovascularization secondary to pathologic myopia: 12-month results

Ranibizumab for the treatment of choroidal neovascularisation secondary to pathological myopia: interim analysis of the REPAIR study

“…The dose was chosen in accordance with the product labelling for treatment of AMD 15 and the dose level used in several recent case series in myopic CNV. [16][17][18][19] The initial dose was followed by repeated injections, administered as needed (PRN) following monthly monitoring with Spectral Domain Optical Coherence Tomography (SD OCT), but no more frequently than every 28 days, for upto a further 11 months. The algorithm used to determine the need for retreatment is presented in Figure 1.…”

Long-term outcome of intravitreal anti-vascular endothelial growth factor therapy with bevacizumab or ranibizumab as primary treatment for subfoveal myopic choroidal neovascularization

“…[8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25] Although the short-term results have demonstrated significant visual improvement following anti-VEGF therapy, the longer term visual outcomes appeared more variable. 14,[26][27][28] In addition, many previous studies have included both treatment naïve cases and previously treated eyes, as well as subfoveal and non-subfoveal CNV in the series, making comparison of results more difficult.…”

“…6,7 In the past few years, various studies have demonstrated the short-term efficacy of intravitreal antivascular endothelial growth factor (VEGF) agents in treating myopic CNV, including both bevacizumab [8][9][10][11][12][13][14][15][16][17][18] and ranibizumab. [18][19][20][21][22][23][24][25] Most of the studies have demonstrated significant mean visual improvement after anti-VEGF therapy and the beneficial effects were maintained at 12 months. In addition, several more recent studies have also reported the longer term visual outcomes of up to 2 years following intravitreal bevacizumab treatment for myopic CNV.…”

Intravitreal bevacizumab for choroidal neovascularisation secondary to causes other than age-related macular degeneration

“…There are two published reports on ranibizumab and one for pegaptanib sodium treatment. [21][22][23] Treatment outcomes after intravitreal bevacizumab in 15 studies are summarised in Table 1. [24][25][26][27][28][29][30][31][32][33][34][35][36][37][38] A cumulative analysis of all study data reveals the following trends.…”